REGN logo

REGN EBIT

annual EBIT:

$4.84B+$562.80M(+13.17%)
December 31, 2024

Summary

  • As of today (May 29, 2025), REGN annual earnings before interest & taxes is $4.84 billion, with the most recent change of +$562.80 million (+13.17%) on December 31, 2024.
  • During the last 3 years, REGN annual EBIT has fallen by -$4.55 billion (-48.47%).
  • REGN annual EBIT is now -48.47% below its all-time high of $9.38 billion, reached on December 31, 2021.

Performance

REGN EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNincome statement metrics

quarterly EBIT:

$913.70M-$54.90M(-5.67%)
March 31, 2025

Summary

  • As of today (May 29, 2025), REGN quarterly earnings before interest & taxes is $913.70 million, with the most recent change of -$54.90 million (-5.67%) on March 31, 2025.
  • Over the past year, REGN quarterly EBIT has increased by +$196.90 million (+27.47%).
  • REGN quarterly EBIT is now -75.75% below its all-time high of $3.77 billion, reached on June 30, 2021.

Performance

REGN quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNincome statement metrics

TTM EBIT:

$5.03B+$196.90M(+4.07%)
March 31, 2025

Summary

  • As of today (May 29, 2025), REGN TTM earnings before interest & taxes is $5.03 billion, with the most recent change of +$196.90 million (+4.07%) on March 31, 2025.
  • Over the past year, REGN TTM EBIT has increased by +$918.90 million (+22.34%).
  • REGN TTM EBIT is now -46.37% below its all-time high of $9.38 billion, reached on December 31, 2021.

Performance

REGN TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNincome statement metrics

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

REGN EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+13.2%+27.5%+22.3%
3 y3 years-48.5%-15.0%-45.3%
5 y5 years+96.6%+35.4%+95.0%

REGN EBIT Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-48.5%+13.2%-44.4%+27.5%-45.3%+22.3%
5 y5-year-48.5%+96.6%-75.8%+35.4%-46.4%+95.0%
alltimeall time-48.5%+2498.2%-75.8%+1640.3%-46.4%+2595.9%

REGN EBIT History

DateAnnualQuarterlyTTM
Mar 2025
-
$913.70M(-5.7%)
$5.03B(+4.1%)
Dec 2024
$4.84B(+13.2%)
$968.60M(-35.7%)
$4.84B(-3.9%)
Sep 2024
-
$1.51B(-8.3%)
$5.03B(+8.1%)
Jun 2024
-
$1.64B(+129.2%)
$4.65B(+13.2%)
Mar 2024
-
$716.80M(-38.5%)
$4.11B(-3.7%)
Dec 2023
$4.27B(-13.1%)
$1.17B(+3.3%)
$4.27B(-4.0%)
Sep 2023
-
$1.13B(+2.4%)
$4.45B(-8.2%)
Jun 2023
-
$1.10B(+25.8%)
$4.84B(+2.7%)
Mar 2023
-
$876.00M(-34.7%)
$4.72B(-4.0%)
Dec 2022
$4.92B(-47.6%)
$1.34B(-12.0%)
$4.92B(-19.3%)
Sep 2022
-
$1.53B(+56.2%)
$6.09B(-4.8%)
Jun 2022
-
$976.30M(-9.2%)
$6.40B(-30.4%)
Mar 2022
-
$1.07B(-57.3%)
$9.19B(-2.1%)
Dec 2021
$9.38B(+142.6%)
$2.52B(+37.5%)
$9.38B(+15.8%)
Sep 2021
-
$1.83B(-51.4%)
$8.11B(+11.0%)
Jun 2021
-
$3.77B(+197.2%)
$7.30B(+63.6%)
Mar 2021
-
$1.27B(+2.3%)
$4.46B(+15.3%)
Dec 2020
$3.87B(+57.3%)
$1.24B(+21.0%)
$3.87B(+9.7%)
Sep 2020
-
$1.02B(+10.3%)
$3.52B(+7.6%)
Jun 2020
-
$928.60M(+37.6%)
$3.28B(+27.0%)
Mar 2020
-
$674.70M(-24.7%)
$2.58B(+4.9%)
Dec 2019
$2.46B(-4.7%)
$896.50M(+15.5%)
$2.46B(+9.5%)
Sep 2019
-
$776.30M(+233.6%)
$2.25B(+6.3%)
Jun 2019
-
$232.70M(-58.0%)
$2.11B(-16.9%)
Mar 2019
-
$553.80M(-19.0%)
$2.54B(-1.5%)
Dec 2018
$2.58B(+22.7%)
$683.60M(+6.3%)
$2.58B(+5.0%)
Sep 2018
-
$643.30M(-3.0%)
$2.46B(+3.0%)
Jun 2018
-
$663.00M(+12.0%)
$2.39B(+5.8%)
Mar 2018
-
$591.80M(+5.5%)
$2.26B(+7.2%)
Dec 2017
$2.10B(+57.3%)
$560.77M(-1.9%)
$2.10B(+11.5%)
Sep 2017
-
$571.79M(+7.6%)
$1.89B(+12.2%)
Jun 2017
-
$531.25M(+20.8%)
$1.68B(+16.5%)
Mar 2017
-
$439.79M(+27.7%)
$1.44B(+8.0%)
Dec 2016
$1.34B(+7.9%)
$344.32M(-6.0%)
$1.34B(+10.8%)
Sep 2016
-
$366.38M(+24.8%)
$1.21B(-2.3%)
Jun 2016
-
$293.51M(-11.8%)
$1.24B(-4.1%)
Mar 2016
-
$332.79M(+55.1%)
$1.29B(+4.0%)
Dec 2015
$1.24B(+55.2%)
$214.53M(-45.6%)
$1.24B(+1.5%)
Sep 2015
-
$394.56M(+13.9%)
$1.22B(+20.0%)
Jun 2015
-
$346.51M(+22.1%)
$1.02B(+14.3%)
Mar 2015
-
$283.73M(+44.7%)
$889.84M(+11.4%)
Dec 2014
$798.61M(+7.5%)
$196.07M(+2.6%)
$798.61M(+0.4%)
Sep 2014
-
$191.06M(-12.8%)
$795.37M(-5.5%)
Jun 2014
-
$218.98M(+13.8%)
$841.74M(+7.7%)
Mar 2014
-
$192.50M(-0.2%)
$781.81M(+5.2%)
Dec 2013
$742.82M(+61.6%)
$192.84M(-18.8%)
$742.82M(+6.7%)
Sep 2013
-
$237.42M(+49.3%)
$696.04M(+5.2%)
Jun 2013
-
$159.06M(+3.6%)
$661.50M(+12.0%)
Mar 2013
-
$153.51M(+5.1%)
$590.42M(+28.4%)
Dec 2012
$459.73M(-328.0%)
$146.05M(-28.0%)
$459.73M(+70.9%)
Sep 2012
-
$202.88M(+130.6%)
$269.07M(+3086.1%)
Jun 2012
-
$87.98M(+285.7%)
$8.45M(-106.1%)
Mar 2012
-
$22.81M(-151.1%)
-$138.85M(-31.1%)
Dec 2011
-$201.61M(+111.4%)
-$44.60M(-22.8%)
-$201.61M(+19.2%)
Sep 2011
-
-$57.74M(-2.7%)
-$169.15M(+18.2%)
Jun 2011
-
-$59.32M(+48.5%)
-$143.04M(+33.9%)
Mar 2011
-
-$39.94M(+229.1%)
-$106.86M(+12.1%)
Dec 2010
-$95.35M(+37.0%)
-$12.14M(-61.6%)
-$95.35M(-19.3%)
Sep 2010
-
-$31.64M(+36.8%)
-$118.13M(+34.6%)
Jun 2010
-
-$23.13M(-18.7%)
-$87.78M(+8.5%)
Mar 2010
-
-$28.44M(-18.6%)
-$80.92M(+19.2%)
Dec 2009
-$69.61M(+0.9%)
-$34.92M(+2604.9%)
-$67.86M(+45.2%)
Sep 2009
-
-$1.29M(-92.1%)
-$46.74M(-28.5%)
Jun 2009
-
-$16.27M(+5.7%)
-$65.38M(-4.9%)
Mar 2009
-
-$15.39M(+11.5%)
-$68.73M(-0.8%)
Dec 2008
-$69.03M(-26.2%)
-$13.79M(-30.8%)
-$69.26M(+50.2%)
Sep 2008
-
-$19.93M(+1.6%)
-$46.10M(-28.9%)
Jun 2008
-
-$19.62M(+23.3%)
-$64.83M(-14.5%)
Mar 2008
-
-$15.91M(-269.9%)
-$75.82M(-19.0%)
Dec 2007
-$93.56M
$9.36M(-124.2%)
-$93.56M(-31.4%)
DateAnnualQuarterlyTTM
Sep 2007
-
-$38.67M(+26.3%)
-$136.41M(+8.3%)
Jun 2007
-
-$30.60M(-9.0%)
-$126.00M(+5.3%)
Mar 2007
-
-$33.65M(+0.5%)
-$119.64M(+11.1%)
Dec 2006
-$107.66M(-186.5%)
-$33.49M(+18.5%)
-$107.66M(-174.2%)
Sep 2006
-
-$28.26M(+16.5%)
$145.15M(+4.4%)
Jun 2006
-
-$24.25M(+11.9%)
$139.02M(+6.0%)
Mar 2006
-
-$21.66M(-109.9%)
$131.10M(+5.4%)
Dec 2005
$124.42M(+2103.7%)
$219.31M(-737.8%)
$124.42M(-236.8%)
Sep 2005
-
-$34.39M(+6.9%)
-$90.92M(+37.7%)
Jun 2005
-
-$32.17M(+13.5%)
-$66.01M(+42.0%)
Mar 2005
-
-$28.34M(-813.1%)
-$46.49M(-923.4%)
Dec 2004
$5.65M(-105.6%)
$3.97M(-141.9%)
$5.65M(-136.5%)
Sep 2004
-
-$9.48M(-25.0%)
-$15.47M(-51.2%)
Jun 2004
-
-$12.64M(-153.1%)
-$31.69M(-33.4%)
Mar 2004
-
$23.79M(-238.8%)
-$47.60M(-52.3%)
Dec 2003
-$99.99M(-18.0%)
-$17.14M(-33.3%)
-$99.78M(-14.9%)
Sep 2003
-
-$25.70M(-10.0%)
-$117.27M(-5.2%)
Jun 2003
-
-$28.56M(+0.6%)
-$123.74M(-1.1%)
Mar 2003
-
-$28.38M(-18.1%)
-$125.14M(+2.6%)
Dec 2002
-$121.95M(+42.3%)
-$34.63M(+7.6%)
-$121.95M(+4.3%)
Sep 2002
-
-$32.18M(+7.4%)
-$116.91M(+8.2%)
Jun 2002
-
-$29.95M(+18.9%)
-$108.03M(+12.3%)
Mar 2002
-
-$25.19M(-14.9%)
-$96.17M(+12.2%)
Dec 2001
-$85.68M(+239.0%)
-$29.59M(+27.0%)
-$85.68M(+30.1%)
Sep 2001
-
-$23.29M(+28.8%)
-$65.88M(+13.4%)
Jun 2001
-
-$18.09M(+22.9%)
-$58.07M(+32.4%)
Mar 2001
-
-$14.71M(+50.3%)
-$43.87M(+16.6%)
Dec 2000
-$25.28M(+6.2%)
-$9.79M(-36.8%)
-$37.64M(+31.8%)
Sep 2000
-
-$15.49M(+298.9%)
-$28.55M(+57.2%)
Jun 2000
-
-$3.88M(-54.2%)
-$18.16M(-19.9%)
Mar 2000
-
-$8.48M(+1111.4%)
-$22.68M(-7.8%)
Dec 1999
-$23.80M(+90.4%)
-$700.00K(-86.3%)
-$24.60M(-17.7%)
Sep 1999
-
-$5.10M(-39.3%)
-$29.90M(+9.9%)
Jun 1999
-
-$8.40M(-19.2%)
-$27.20M(+50.3%)
Mar 1999
-
-$10.40M(+73.3%)
-$18.10M(+43.7%)
Dec 1998
-$12.50M(-8.8%)
-$6.00M(+150.0%)
-$12.60M(+8.6%)
Sep 1998
-
-$2.40M(-442.9%)
-$11.60M(+12.6%)
Jun 1998
-
$700.00K(-114.3%)
-$10.30M(-29.9%)
Mar 1998
-
-$4.90M(-2.0%)
-$14.70M(+5.8%)
Dec 1997
-$13.70M(-20.8%)
-$5.00M(+354.5%)
-$13.90M(+3.7%)
Sep 1997
-
-$1.10M(-70.3%)
-$13.40M(-19.8%)
Jun 1997
-
-$3.70M(-9.8%)
-$16.70M(0.0%)
Mar 1997
-
-$4.10M(-8.9%)
-$16.70M(-3.5%)
Dec 1996
-$17.30M(+127.6%)
-$4.50M(+2.3%)
-$17.30M(+11.6%)
Sep 1996
-
-$4.40M(+18.9%)
-$15.50M(+14.8%)
Jun 1996
-
-$3.70M(-21.3%)
-$13.50M(+21.6%)
Mar 1996
-
-$4.70M(+74.1%)
-$11.10M(+30.6%)
Dec 1995
-$7.60M(-74.0%)
-$2.70M(+12.5%)
-$8.50M(-22.0%)
Sep 1995
-
-$2.40M(+84.6%)
-$10.90M(-10.7%)
Jun 1995
-
-$1.30M(-38.1%)
-$12.20M(-41.6%)
Mar 1995
-
-$2.10M(-58.8%)
-$20.90M(-28.4%)
Dec 1994
-$29.20M(-24.7%)
-$5.10M(+37.8%)
-$29.20M(-17.3%)
Sep 1994
-
-$3.70M(-63.0%)
-$35.30M(-13.7%)
Jun 1994
-
-$10.00M(-3.8%)
-$40.90M(+0.5%)
Mar 1994
-
-$10.40M(-7.1%)
-$40.70M(+3.0%)
Dec 1993
-$38.80M(+112.0%)
-$11.20M(+20.4%)
-$39.50M(+14.8%)
Sep 1993
-
-$9.30M(-5.1%)
-$34.40M(+12.1%)
Jun 1993
-
-$9.80M(+6.5%)
-$30.70M(+25.8%)
Mar 1993
-
-$9.20M(+50.8%)
-$24.40M(+32.6%)
Dec 1992
-$18.30M(+90.6%)
-$6.10M(+8.9%)
-$18.40M(+15.0%)
Sep 1992
-
-$5.60M(+60.0%)
-$16.00M(+24.0%)
Jun 1992
-
-$3.50M(+9.4%)
-$12.90M(+13.2%)
Mar 1992
-
-$3.20M(-13.5%)
-$11.40M(+83.9%)
Dec 1991
-$9.60M(+190.9%)
-$3.70M(+48.0%)
-$6.20M(-34.7%)
Sep 1991
-
-$2.50M(+25.0%)
-$9.50M(+66.7%)
Jun 1991
-
-$2.00M(-200.0%)
-$5.70M(+128.0%)
Mar 1991
-
$2.00M(-128.6%)
-$2.50M(-24.2%)
Dec 1990
-$3.30M
-$7.00M(-638.5%)
-$3.30M(-189.2%)
Sep 1990
-
$1.30M(+8.3%)
$3.70M(+54.2%)
Jun 1990
-
$1.20M(0.0%)
$2.40M(+100.0%)
Mar 1990
-
$1.20M
$1.20M

FAQ

  • What is Regeneron Pharmaceuticals annual earnings before interest & taxes?
  • What is the all time high annual EBIT for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals annual EBIT year-on-year change?
  • What is Regeneron Pharmaceuticals quarterly earnings before interest & taxes?
  • What is the all time high quarterly EBIT for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals quarterly EBIT year-on-year change?
  • What is Regeneron Pharmaceuticals TTM earnings before interest & taxes?
  • What is the all time high TTM EBIT for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals TTM EBIT year-on-year change?

What is Regeneron Pharmaceuticals annual earnings before interest & taxes?

The current annual EBIT of REGN is $4.84B

What is the all time high annual EBIT for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high annual earnings before interest & taxes is $9.38B

What is Regeneron Pharmaceuticals annual EBIT year-on-year change?

Over the past year, REGN annual earnings before interest & taxes has changed by +$562.80M (+13.17%)

What is Regeneron Pharmaceuticals quarterly earnings before interest & taxes?

The current quarterly EBIT of REGN is $913.70M

What is the all time high quarterly EBIT for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high quarterly earnings before interest & taxes is $3.77B

What is Regeneron Pharmaceuticals quarterly EBIT year-on-year change?

Over the past year, REGN quarterly earnings before interest & taxes has changed by +$196.90M (+27.47%)

What is Regeneron Pharmaceuticals TTM earnings before interest & taxes?

The current TTM EBIT of REGN is $5.03B

What is the all time high TTM EBIT for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high TTM earnings before interest & taxes is $9.38B

What is Regeneron Pharmaceuticals TTM EBIT year-on-year change?

Over the past year, REGN TTM earnings before interest & taxes has changed by +$918.90M (+22.34%)
On this page